Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration
- PMID: 27470241
- PMCID: PMC5064161
- DOI: 10.1093/cid/ciw506
Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration
Abstract
Background: Mass drug administration (MDA) with praziquantel is the cornerstone of schistosomiasis control in sub-Saharan Africa. The effectiveness of this strategy is dependent on the continued high efficacy of praziquantel; however, drug efficacy is rarely monitored using appropriate statistical approaches that can detect early signs of wane.
Methods: We conducted a repeated cross-sectional study, examining children infected with Schistosoma mansoni from 6 schools in Uganda that had previously received between 1 and 9 rounds of MDA with praziquantel. We collected up to 12 S. mansoni egg counts from 414 children aged 6-12 years before and 25-27 days after treatment with praziquantel. We estimated individual patient egg reduction rates (ERRs) using a statistical model to explore the influence of covariates, including the number of prior MDA rounds.
Results: The average ERR among children within schools that had received 8 or 9 previous rounds of MDA (95% Bayesian credible interval [BCI], 88.23%-93.64%) was statistically significantly lower than the average in schools that had received 5 rounds (95% BCI, 96.13%-99.08%) or 1 round (95% BCI, 95.51%-98.96%) of MDA. We estimate that 5.11%, 4.55%, and 16.42% of children from schools that had received 1, 5, and 8-9 rounds of MDA, respectively, had ERRs below the 90% threshold of optimal praziquantel efficacy set by the World Health Organization.
Conclusions: The reduced efficacy of praziquantel in schools with a higher exposure to MDA may pose a threat to the effectiveness of schistosomiasis control programs. We call for the efficacy of anthelmintic drugs used in MDA to be closely monitored.
Keywords: anthelmintic efficacy; generalized linear mixed model; parasite; praziquantel; schistosomiasis.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures




Similar articles
-
Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns.Acta Trop. 2013 Nov;128(2):292-302. doi: 10.1016/j.actatropica.2012.09.010. Epub 2012 Sep 26. Acta Trop. 2013. PMID: 23022016
-
Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.Parasit Vectors. 2016 Oct 24;9(1):560. doi: 10.1186/s13071-016-1833-6. Parasit Vectors. 2016. PMID: 27772528 Free PMC article.
-
Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda.Parasit Vectors. 2019 Dec 27;12(1):607. doi: 10.1186/s13071-019-3860-6. Parasit Vectors. 2019. PMID: 31881923 Free PMC article.
-
Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis.PLoS Negl Trop Dis. 2019 Oct 11;13(10):e0007808. doi: 10.1371/journal.pntd.0007808. eCollection 2019 Oct. PLoS Negl Trop Dis. 2019. PMID: 31603895 Free PMC article.
-
SCORE Studies on the Impact of Drug Treatment on Morbidity due to Schistosoma mansoni and Schistosoma haematobium Infection.Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):30-35. doi: 10.4269/ajtmh.19-0830. Am J Trop Med Hyg. 2020. PMID: 32400348 Free PMC article.
Cited by
-
In Vitro Cercaricidal and Schistosomicidal Activities of the Raffia Wine and Hydroethanolic Extracts of Pedilanthus tithymaloides Linn (Poit). Stem Barks.Evid Based Complement Alternat Med. 2022 Sep 16;2022:2672150. doi: 10.1155/2022/2672150. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36159554 Free PMC article.
-
Mitochondria as a Potential Target for the Development of Prophylactic and Therapeutic Drugs against Schistosoma mansoni Infection.Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0041821. doi: 10.1128/AAC.00418-21. Epub 2021 Aug 2. Antimicrob Agents Chemother. 2021. PMID: 34339272 Free PMC article.
-
Risk factor analysis of equine strongyle resistance to anthelmintics.Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):407-415. doi: 10.1016/j.ijpddr.2017.10.007. Epub 2017 Nov 2. Int J Parasitol Drugs Drug Resist. 2017. PMID: 29149701 Free PMC article.
-
A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies.J Infect Dis. 2017 Dec 12;216(11):1425-1433. doi: 10.1093/infdis/jix496. J Infect Dis. 2017. PMID: 28968877 Free PMC article. Clinical Trial.
-
Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial.Nat Med. 2024 Jan;30(1):130-137. doi: 10.1038/s41591-023-02719-4. Epub 2024 Jan 4. Nat Med. 2024. PMID: 38177851 Free PMC article. Clinical Trial.
References
-
- Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis 2004; 17:439–47. - PubMed
-
- van der Werf MJ, de Vlas SJ, Brooker S et al. . Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003; 86:125–39. - PubMed
-
- el Gaddal AA. The Blue Nile Health Project: a comprehensive approach to the prevention and control of water-associated diseases in irrigated schemes of the Sudan. J Trop Med Hyg 1985; 88:47–56. - PubMed
-
- Fenwick A, Webster JP. Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 2006; 19:577–82. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous